Recent research is challenging the long-standing practice of removing lymph nodes during cancer surgery, a procedure that has historically saved countless lives. New findings suggest that while this method has been pivotal in detecting cancer spread, it may also compromise the body’s immune defenses in ways that were not previously understood.
Surgeons typically remove lymph nodes for two main purposes: to determine whether cancer has metastasized and to prevent further spread to other organs. For decades, this approach has been the gold standard in cancer treatment. When a tumor escapes its original site, cancer cells often travel through lymph vessels and settle in nearby lymph nodes, which act as biological filters. The presence of cancer cells in these nodes indicates a higher likelihood of recurrence after treatment.
However, lymph nodes are more than passive filters; they are active participants in the immune response. They serve as vital communication hubs for immune cells, particularly a type known as CD8 positive T cells, which are essential for destroying cancer cells. Recent studies indicate that lymph nodes help maintain these T cells, priming them for action. Removing these nodes may weaken the body’s anti-cancer immune response, especially during immunotherapy treatments, which rely on the patient’s natural immunity.
While laboratory studies have demonstrated the crucial roles of lymph nodes, this knowledge has yet to be fully applied to human patients. The removal of lymph nodes is not without its drawbacks. Patients can suffer from complications such as swelling, known as lymphoedema, increased infection risk, and chronic pain. There is also concern that removing these nodes could inadvertently weaken long-term immune defenses.
Despite these risks, lymph node removal remains a common practice in treating solid tumors, as their involvement is one of the best predictors of cancer recurrence. To mitigate risks, doctors often employ a technique known as sentinel node biopsy, which involves removing only the first lymph node that drains from a tumor. This method reduces the number of nodes removed and minimizes side effects, allowing for a more targeted approach.
Research is increasingly revealing that lymph nodes are dynamic environments where immune cells grow and multiply. This is particularly important during treatments such as checkpoint blockade immunotherapy, which are becoming standard for various cancers. These findings suggest that while lymph node removal can halt cancer spread, it may also eliminate crucial sites for immune system activation.
In recent years, hospitals have begun adopting less invasive surgical techniques, focusing on minimizing disruption by only removing nodes that are most likely to harbor cancer. This shift not only reduces complications but may also help preserve patients’ immune function. Some patients with early-stage cancers may even avoid lymph node removal altogether, relying on imaging and biopsies to monitor for potential spread.
Emerging therapies offer hope for those concerned about the effects of lymph node removal. New immunotherapy drugs, targeted treatments, and cancer vaccines are being developed to help “re-educate” the immune system, even in patients who have lost some lymph nodes. Evidence is mounting that retaining at least some lymph nodes is beneficial for maintaining the body’s ability to combat lingering cancer cells.
Looking ahead, cancer surgery may become more personalized. By mapping activity within lymph nodes, healthcare providers can identify which nodes are essential for immune function and which are likely to contribute to tumor recurrence. This knowledge could lead to tailored surgical strategies that maximize benefits while minimizing harm.
The question of whether to remove lymph nodes during cancer surgery is complex. For many patients, it remains a vital and potentially lifesaving procedure. However, ongoing research highlights the importance of understanding lymph nodes as active participants in immune response, raising the potential for smarter surgical approaches that preserve the body’s natural defenses. As noted by Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University, the future of cancer surgery may involve a careful balance: weighing immediate surgical benefits against long-term immune implications.
